The company's portfolio includes product candidates in immunology, rare disease, infectious disease, and central nervous system (CNS) fields. They are developing biologics to address organ transplant rejection, autoimmunity, and cancer, as well as next-generation vaccines for COVID-19 and Smallpox/Monkeypox prevention. Tonix Pharmaceuticals is also working on small molecules and biologics to treat pain, neurologic, psychiatric, and addiction conditions. Their goal is to provide novel drug therapies and vaccines to improve population health worldwide.